Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech’s Share Of Private Investment Dollars In 2012

This article was originally published in Start Up

Executive Summary

Each year, START-UP reviews the sectors of the medical device industry that received private funding to see what will be filling the pipelines of medical device companies in the future. Despite gloomy talk by VCs and strategics predicting a future scarcity of new innovative products, the actual data from 2012 show many categories holding steady and pockets of up-and-coming technologies attracting investment.

You may also be interested in...



Medtech VCs Show Steady Hand With Dollars Invested in 2013

Despite contraction in the number of funds and VC firms investing in life sciences, 2013 was a strong year for private investing in medtech, with private investors putting $2.54 million into 129 medical device deals, according to Informa’s Strategic Transactions. Looking at where investors placed their money revealed some emerging trends.

Edwards Acquires BMEYE, Gains Noninvasive Hemodynamic Monitoring

Edwards Lifesciences announced that it was acquiring private Dutch company BMEYE BV, the developer of a new noninvasive technology for hemodynamic monitoring. Noninvasive hemodynamic monitoring has long been “The Holy Grail” in critical care, and non-invasive technology opens up new applications and new markets for Edwards as well.

In Cartilage Repair Histogenics Resets The Stage

In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel